FDA wants new warning added to weight loss drugs for possible risk of vision loss
Original headlineFDA, zayıflama ilaçlarına olası görme kaybı riski için yeni uyarı eklenmesini istiyor
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
The FDA has asked manufacturers of GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound to add a label warning for a rare eye condition that can cause severe vision loss, a risk also under review in Europe. The requested warning would apply to semaglutide-based therapies, which patients and prescribers may need to monitor more closely. The move affects some of the world's fastest-selling diabetes and weight-loss treatments, raising scrutiny of side effects as demand for the drug class continues to surge.
Muhabbit's AI wrote this summary in its own words from Ekonomim's report and translated it from Turkish. It can get details wrong, so check the source.
Named in this story
FDA, Zepbound, Mounjaro, Ozempic, Wegovy, semaglutide